← Back to Clinical Trials
Recruiting NCT06369532

NCT06369532 Combination of Neurostimulation and Psychotherapy to Stop Worrying

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06369532
Status Recruiting
Phase
Sponsor University Hospital, Ghent
Condition Active tDCS
Study Type INTERVENTIONAL
Enrollment 85 participants
Start Date 2024-03-06
Primary Completion 2027-09-26

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 70 Years
Study Type INTERVENTIONAL
Interventions
Active tDCSSham tDCS

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 85 participants in total. It began in 2024-03-06 with a primary completion date of 2027-09-26.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study aims to investigate whether the combination of transcranial Direct Current Stimulation (tDCS) and cognitive-behavioral therapy (CBT) is more effective for treating repetitive negative thinking (RNT) in patients with the symptom of high rumination. High ruminators will be included (Group1, active tDCS-CBT group; Group2, sham tDCS-CBT group). All patients will receive active or sham tDCS.

Eligibility Criteria

Inclusion Criteria: * Generalized anxiety disorder (GAD) * Depressive disorder Exclusion Criteria: * other psychiatric pathology than GAD or depression screened by senior psychiatrist by means of the Mini-International Neuropsychiatric Interview (MINI) and psychiatric anamnesis * Abuse of alcohol, drugs or medication other than prescribed by general practitioner or psychiatrist * no consent to participate in measurement (questionnaire, fNIRS or EEG) * Insufficient knowledge of the current language (Dutch) * Acute or chronic suicidality * Acute psychosis or manic depressive disorder * Inability to commit to 8 sessions of Cognitive-Behavioral Therapy (CBT) or receive 4 weeks of transcranial Direct Current Stimulation (tDCS).

Contact & Investigator

Central Contact

Chris Baeken

✉ Chris.Baeken@ugent.be

📞 +32476209841

Principal Investigator

Chris Baeken

PRINCIPAL INVESTIGATOR

University Ghent

Frequently Asked Questions

Who can join the NCT06369532 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Active tDCS. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06369532 currently recruiting?

Yes, NCT06369532 is actively recruiting participants. Contact the research team at Chris.Baeken@ugent.be for enrollment information.

Where is the NCT06369532 trial being conducted?

This trial is being conducted at Ghent, Belgium.

Who is sponsoring the NCT06369532 clinical trial?

NCT06369532 is sponsored by University Hospital, Ghent. The principal investigator is Chris Baeken at University Ghent. The trial plans to enroll 85 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology